Boehringer Ingelheim’s Ofev (nintedanib) slows scarring in idiopathic pulmonary fibrosis patients’ lungs, a Phase 3b trial indicates. The company used an imaging technique to check on Ofev’s anti-fibrotic properties. It was the ... Read more